Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition | Circulation
VALSARTAN
Olmesartan | C24H26N6O3 | CID 158781 - PubChem
File:Valsartan.svg - Wikipedia
Frontiers | Neprilysin Inhibitors and Bradykinin
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Heart failure with preserved ejection fraction: emerging drug strategies. - Abstract - Europe PMC
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure | NEJM
Sacubitril | New Drug Approvals
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
Frontiers | Neprilysin Inhibitors and Bradykinin
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Entresto | C96H120N12Na6O21 | CID 71449007 - PubChem
Sacubitril - Wikipedia
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Bio <-> Chem: Back-story on Novartis LCZ696 database links
Neprilysin - Wikipedia
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Sacubitril/valsartan - Wikipedia
